Výsledky vyhledávání

Akademický článek

The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening

Autor: G. Hoste, K. Vossaert, W. A. J. Poppe

Publikováno v: Obstetrics and Gynecology International, Vol 2013 (2013)

Traditional population-based cervical screening programs, based on cytology, have successfully reduced the burden of cervical cancer. Nevertheless limitations remain and new screening methods are emerging. Despite vaccination against the 2 most oncog

Externí odkaz: https://doaj.org/article/9c38a00dd35f45979732627c6faf952d

Zobrazit plný text záznamu

Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2− early breast cancer

Autor: Ines Nevelsteen, Ann Smeets, Chantal Van Ongeval, Hans Wildiers, Anne-Sophie Van Rompuy, Laurence Slembrouck, Caroline Weltens, G Hoste, Els Van Nieuwenhuysen, Giuseppe Floris, Isabelle Vanden Bempt, Kevin Punie, Patrick Neven, Lynn Jongen, Sileny Han

Publikováno v: Modern Pathology. 34:1297-1309

Multigene signatures (MGS) are used to guide adjuvant chemotherapy (aCT) decisions in patients diagnosed with estrogen receptor (ER)-positive HER2-negative early breast cancer. We used results from three MGS (Oncotype DX® (ODX), MammaPrint® (MP) or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029f117e5edbb3070e6dca02e8b0ba8b
https://doi.org/10.1038/s41379-021-00743-8

Zobrazit plný text záznamu

Abstract P3-07-14: Multigene signatures based risk estimates in early ER+/HER2- breast cancer: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use

Autor: Sileny Han, Erik Van Limbergen, Ines Nevelsteen, Ann Smeets, Lynn Jongen, Hans Wildiers, Isabelle Vanden Bempt, Giuseppe Floris, Philippe Moerman, Laurence Slembrouck, Patrick Neven, Kevin Punie, Caroline Weltens, G Hoste, Els Van Nieuwenhuysen

Publikováno v: Cancer Research. 80:P3-07

Background Multigene signatures (MGS) select women with estrogen receptor positive human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancers where adjuvant chemotherapy (aCT) can be avoided. However, MGS are expensive and not alway

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7704adc3e02b8a13a69885a5d0931434
https://doi.org/10.1158/1538-7445.sabcs19-p3-07-14

Zobrazit plný text záznamu

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

Publikováno v: Translational Oncology, Vol 12, Iss 12, Pp 1557-1565 (2019)
Translational Oncology

A previously developed and centrally validated MammaPrint® (MP) and BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b312847395e353c90474276695b5c1
http://www.sciencedirect.com/science/article/pii/S1936523319303511

Zobrazit plný text záznamu

Abstract P6-08-03: Germline mutational landscape in 5422 individuals at risk for hereditary breast and ovarian cancer who underwent multi-gene panel testing

Autor: Machteld Keupers, Chantal Van Ongeval, Eric Legius, Hilde Brems, Patrick Neven, Ellen Denayer, Hilde Van Esch, Renate Prevos, Christine Desmedt, G Hoste, Ines Nevelsteen, Jan Ardui, H. Wildiers, Hilde Peeters, A Smeets, K Punie, Griet Van Buggenhout, Giuseppe Floris, Geneviève Michils

Publikováno v: Cancer Research. 80:P6-08

Background: The introduction of multi-gene panel testing and improved awareness under patients and physicians has led to an increase of individuals with known germline pathogenic variants in hereditary breast and ovarian cancer (HBOC) genes. Signific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a707942f889ea199f39afedec2e1113a
https://doi.org/10.1158/1538-7445.sabcs19-p6-08-03

Zobrazit plný text záznamu

Abstract P4-08-25: Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute Paris

Publikováno v: Cancer Research. 79:P4-08

Background Many countries restrict patient material exchange to central diagnostic laboratories abroad, limiting access to assays like MammaPrint® (MP) and BluePrint® (BP). Both assays are microarray-based, with MP being prognostic for distant recu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26884e68e7d8efc70058ac9231827730
https://doi.org/10.1158/1538-7445.sabcs18-p4-08-25

Zobrazit plný text záznamu

Abstract P5-09-05: Hereditary breast cancer beyond BRCA: Clinical and histopathological characteristics in patients with germline CHEK2, ATM, PALB2 and TP53-mutations

Autor: Patrick Neven, Eric Legius, G Van Buggenhout, Guiseppe Floris, Sileny Han, Caroline Weltens, P D'Hoore, Patrick Berteloot, K Punie, A Smeets, E Van Nieuwenhuysen, H. Wildiers, Hilde Janssen, G Hoste, E. Van Limbergen, Ines Nevelsteen

Publikováno v: Cancer Research. 79:P5-09

Background The introduction of multi-gene panel testing in the diagnosis of hereditary breast and ovarian cancer (HBOC) has led to an important increase in the detection of breast cancer predisposition genes other than BRCA1 and BRCA2. Methods All in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::691c4af1301c009d656fd8d838c9fe02
https://doi.org/10.1158/1538-7445.sabcs18-p5-09-05

Zobrazit plný text záznamu

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Autor: Laurence Slembrouck, G Hoste, Johan Menten, Hans Wildiers, Carlos L. Arteaga, Isabelle Vanden Bempt, Giuseppe Floris, Kevin Punie, Tom Matton, Lynn Jongen, Sara Vander Borght, Patrick Neven

Publikováno v: Clinical Drug Investigation. 38:1071-1075

We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca1c7fe215157ad69ca970269549659
https://doi.org/10.1007/s40261-018-0696-3

Zobrazit plný text záznamu

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer

Autor: Benoit Beuselinck, I. Lefever, Nicole Concin, Ignace Vergote, Hans Wildiers, G Hoste, Patrick Berteloot, E Van Nieuwenhuysen, R Salihi, Sileny Han, Patrick Neven, Kevin Punie

Publikováno v: Breast Cancer Research and Treatment. 171:131-141

We aimed to investigate the role of palbociclib, a first-in-class cyclin-dependent kinase 4 and 6 inhibitor, in postmenopausal women with highly pretreated endocrine therapy-resistant metastatic breast cancer (MBC). Between 28 September 2015 and 14 M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21379393fe542f0c95209e497d1efd4d
https://doi.org/10.1007/s10549-018-4827-6

Zobrazit plný text záznamu

Juvenile Papillomatosis: A Case Report

Autor: Patrick Neven, Machteld Keupers, Tom Langenaeken, G Hoste, Valerie Vandeweerd

Juvenile papillomatosis of the breast, also known as Swiss cheese disease, is a rare and benign proliferative disorder affecting young women. These patients tend to have a strong family history of cancer. The lesion typically presents as a localized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e5c48d00778112fada72ae06a6db3d
https://europepmc.org/articles/PMC6456279/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání